MRK · News · 20260902N

Melanoma Vaccine Collaboration

Merck & Co., Inc. · 2026-09-02 · Importance 34 · Surprise 42

Merck and Moderna reported positive Phase 3 results for a personalized mRNA-based cancer therapy in melanoma, focused on reducing recurrence. The collaboration has driven a significant increase in investor attention to Moderna’s oncology pipeline, with Moderna shares reportedly rising 143% over one month. The development strengthens Merck’s longer-term oncology pipeline beyond Keytruda and supports the partners’ continued clinical and commercial development efforts.

Key facts

• Jim Cramer cited an mRNA-based vaccine developed with Merck for melanoma recurrence as a clinical breakthrough driving investor interest in Moderna. source